NEW YORK / Jun 26, 2023 / Business Wire / Politan Capital Management (together with its affiliates, “Politan”), a 9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today commented on the outcome of the Company’s Annual Meeting of Stockholders (the “Annual Meeting”).
Both of Politan’s nominees – Michelle Brennan and Quentin Koffey – were overwhelmingly elected to the Board. Based on preliminary analysis from Politan’s proxy solicitor, each of Politan’s nominees received at least 70% of the total votes cast, with 17 of the top 20 (and 43 of the top 50) shareholders voting for both Politan’s candidates.1
Mr. Koffey, Managing Partner and Chief Investment Officer of Politan, stated:
“Michelle and I would like to thank our fellow shareholders for their support and engagement throughout this campaign, and we look forward to continuing this dialogue as directors. We believe this election represents a clear mandate from shareholders that significant change is needed at Masimo. We are now fully focused on putting the election behind us and working constructively with the incumbent directors to improve the Company’s corporate governance, enhance capital allocation and instill better strategic oversight. We look forward to helping Masimo reach its full potential for all its stakeholders.”
_________________________
1 Numbers exclude voting by company insiders.
Last Trade: | US$111.53 |
Daily Change: | -2.74 -2.40 |
Daily Volume: | 315,987 |
Market Cap: | US$5.930B |
August 27, 2024 August 26, 2024 August 12, 2024 August 06, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB